Generic prescribing report for "ghost" generics
This new report highlights the potential cost pressure for generics prescribed with the manufacturers name stated and has been developed to help CCGs maximise QIPP savings available.
This problem occurs mainly occurs with SystmOne and we are developing a set of searches to help identify patients where the prescription will need to be changed to state just the generic name. These searches should be available w/c 4 February.